ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1593099
This article is part of the Research TopicIncreasing Importance of Patients-generated Real World Data for Healthcare Policy Decisions about Medicinal Products: Volume IIIView all 8 articles
Effects of national volume-based procurement policy on the usage and expenditure of platinum antineoplastic drugs in China: an interrupted time series study
Provisionally accepted
- Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Digestive tract tumors are the common tumors in China. Platinum-based chemotherapy drugs, especially oxaliplatin, play an important role in the treatment of gastrointestinal tumors. Starting from October 2021, the 5 th national centralized volume-based procurement (NCVBP) was implemented in China to reduce the price of oxaliplatin. However, the effect of the policy on platinum antineoplastic drugs is uncertain. This study aims to explore the impact of NCVBP policy on the usage and expenditure of platinum antineoplastic drugs in China.Methods: Oxaliplatin and alternative drugs were used as objects of study to explore the impact of NCVBP policy from the first quarter of 2017 to the second quarter of 2024, while October 2021 was the implementation time point of the policy. Quarterly data was collected from the Chemical Drug Terminal of China's Public Medical Institutions database in 1805 sample public hospitals and more than 3000 urban public hospitals in China. Descriptive analysis was conducted using purchase volume, expenditure and daily cost as variables. Interrupted time-series (ITS) analysis was applied to further analyze the effect of NCVBP policy on the medicines under study.Results: The average volume of bid-winning drug of oxaliplatin increased by 623.66% after the implementation of the policy, and its expenditure increased by 7.92%. The decline in price had promoted the increase in consumption, and the policy had realized the exchange of price for quantity. After the implementation of NCVBP, a significant increase was associated with the volume of bidwinning drugs (P < 0.001) and the trend change was statistically significant (P < 0.001), with an upward trend. The volume of non-winning drugs and the branded drug decreased immediately after policy intervention (P < 0.001).The policy had an influence on promotion of generic substitution and the decrease in expenditures for platinum antineoplastic drugs while ensuring the usage of drugs. The third-generation platinum antineoplastic medications introduced into the 5 th NCVBP policy had no major influence on the use of first-and second-generation platinum antineoplastic treatments. Although the general situation for alternative pharmaceuticals was largely steady, with no expected increase in costs and expenditures, monitoring of alternative drugs was required.
Keywords: National Volume-based Drug Procurement, Platinum-based Chemotherapy Drugs, Interrupted Time Series, Gastrointestinal tumors, oxaliplatin
Received: 13 Mar 2025; Accepted: 31 Jul 2025.
Copyright: © 2025 Yu, Lin, Li, Fu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xihui Yu, Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.